PitchBook：2026年医疗保健展望报告（英文版）

2026 should see rebound in activity across biopharma and healthcare services with continued strength in healthtech and HCIT. • Early indications are that AI is improving clinical trial success rates, potentially doubling historical norms. • We provide a full analysis by clinical phase along with ramification for early-stage life science investor return profiles. The bottom-line is that funding in the early stage has been weak, and prospective return profiles have never been better. We provide